Objectives: To investigate the impact of fractionated stereotactic body radiotherapy (SBRT) on liver function and identify any dosimetric parameters that may predict deterioration of liver function in patients with hepatitis B (HBV)-related hepatocellular carcinoma (HCC). Methods: Thirty-six eligible patients with HBV-related HCC who were treated with fractionated SBRT between January 2008 and December 2010 were assessed. The treatment prescription ranged from 20 to 40 Gy (median, 32 Gy) in 5 to 10 fractions over 1 to 2 weeks. All the patients received pre-emptive antiviral therapy. The median gross tumour volume was 509 cm 3 (range, 2-3088 cm 3). Four liver toxicity endpoints were assessed: (1) rate of HBV reactivation; (2) rate of chronic hepatitis B exacerbation; (3) rate of radiotherapy-induced liver disease; and (4) rate of deterioration in Child-Pugh class. Clinical and dosimetric parameters were evaluated to identify the significant predictors of liver toxicity. Results: No patient developed HBV reactivation, chronic hepatitis B exacerbation, or radiotherapy-induced liver disease within 3 months after SBRT. Four (11%) experienced Child-Pugh class deterioration. On univariate analysis, no clinical and dosimetric parameters were identified as predictors of Child-Pugh class deterioration. Conclusion: SBRT with individualised dosing of up to 40 Gy in 10 fractions can be delivered safely to patients with large unresectable HBV-related HCC in palliative setting. Pre-emptive antiviral therapy is probably mandatory to prevent HBV-related complications in this setting.
Objective: To assess the long-term effectiveness of palliative stereotactic body radiotherapy (SBRT) in patients with large unresectable Barcelona Clinic Liver Cancer stage C hepatitis B-related hepatocellular carcinomas (HCCs). Methods: Consecutive HCC cases treated with fractionated SBRT between January 2008 and December 2010 were analysed. The long-term survival and response rate were evaluated. Univariate and multivariate analyses were performed to identify the significant predictors of survival. Results: In total, 32 cases were analysed, with median gross tumour volume was 509.5 cm 3 (range, 2.2-3088 cm 3 ). Median treatment prescription was 32 Gy (range, in five to 10 fractions over 1 to 2 weeks. Median followup was 13.4 months; median survival was 13.3 months (95% confidence interval [CI]=11.4-15.2). Stable and partial tumour response rates by RECIST criteria were 69% and 31%, respectively. Alpha-fetoprotein reduction at ≥3 months after radiotherapy (p = 0.018) and gain in body weight after SBRT (p < 0.001) were significantly associated with longer survival after multivariate analysis.
Conclusion: SBRT with dose individualisation can be delivered safely to large unresectable tumours in patients withHBV-related HCC. The median survival after SBRT in this study was 13.3 months. Alpha-fetoprotein reduction at ≥3 months and weight gain after radiotherapy were positive prognostic factors for longer survival. More prospective studies are warranted to confirm these results.
Introduction: This study aims to determine the outcomes of stereotactic body radiotherapy (SBRT) for liver metastases in patients not eligible for surgery.Methods: This study included 31 consecutive patients with unresectable liver metastases who received SBRT between January 2012 and December 2017; 22 patients had primary colorectal cancer and nine patients had primary non-colorectal cancer. Treatments ranged from 24 Gy to 48 Gy in 3 to 6 fractions over 1 to 2 weeks. Survival, response rates, toxicities, clinical characteristics, and dosimetric parameters were evaluated. Multivariate analysis was performed to identify significant prognostic factors for survival.Results: Among these 31 patients, 65% had received at least one prior regimen of systemic therapy for metastatic disease, whereas 29% had received chemotherapy for disease progression or immediately after SBRT. The median follow-up interval was 18.9 months; actuarial in-field local control rates at 1, 2, and 3 years after SBRT were 94%, 55%, and 42%, respectively. The median survival duration was 32.9 months; 1-year, 2-year, and 3-year actuarial survival rates were 89.6%, 57.1%, and 46.2%, respectively. The median time to progression
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.